



The adaptive regulation of thiamine pyrophosphokinase-1 facilitates malignant growth during supplemental thiamine conditions


SUPPLEMENTARY MATERIALS




Supplementary Figure 1: mRNA expression of TPK1 in wild type and HIF-1 $\alpha^{-/-}$ HCT 116 cells. Relative mRNA expression level of *TPK1* determined by qRT-PCR analysis in wild type and HIF-1 $\alpha^{-/-}$ HCT 116 cells seeded at 1250 cells/cm² and cultured for 96 h normalized by the 2^{- Δ Ct} method.




Supplementary Figure 2: *Ex Vitro* functionality of TPK1 overexpression in HCT 116 cells. HPLC analysis demonstrating *ex vitro* TPP production as fold change in TPP \pm SD established in lysates isolated from wild type HCT 116 transfected with pcDNA-*TPK1* (TPK1 OE) vector for 72 h relative to control (CTL) cells. (*) Represents statistically significant difference ($p < 0.05$) based on results of an unpaired student's *t*-test.




Supplementary Figure 3: Thiamine levels in wild type and HIF-1 $\alpha^{-/-}$ HCT 116 cells. HPLC analysis demonstrating intracellular thiamine level \pm SD established in wild type and HIF-1 $\alpha^{-/-}$ HCT 116 cells seeded at 1250 cells/cm² and cultured for 96 h.




Supplementary Figure 4: Thiamine and TMP levels in HCT 116 cells treated with NaF, MTX, TRLX and MitoQ. HPLC analysis demonstrating intracellular (A) thiamine and (B) TMP levels \pm SD established in wild type HCT 116 cells seeded at 25,000 cells/cm² and pretreated with 500 μ M NaF, 100 μ M MTX, 500 μ M TRLX or 10 μ M MitoQ for 12 h prior to hypoxic exposure for 24 h with sustained exposure to each compound. (*) Represents statistically significant difference ($p < 0.05$) based on results of an unpaired student's *t*-test. (#) Represents concentration result below the limits of quantification for assay design.




Supplementary Figure 5: Thiamine levels in wild type HCT 116 cells grown under physiological and supplemental thiamine conditions. HPLC analysis demonstrating intracellular thiamine levels \pm SD established in wild type HCT 116 cells exposed to 10 nM or 3 μ M thiamine for 5 d prior to seeding at 50,000 cells/cm² and exposure to 1% O₂ for 24 h. (*) Represents statistically significant difference ($p < 0.05$) based on results of one-way ANOVA with Tukey's post-hoc test for multiple comparisons.



Supplementary Figure 6: Thiamine levels following TPK1 knockdown and overexpression in HCT 116 cells. HPLC analysis demonstrating mean intracellular thiamine levels \pm SD established in wild type HCT 116 cells transfected with (A) SCR CTL and TPK1 KD1 siRNA or (B) VCTR CTL and TPK1 OE vectors for 72 h. (*) Represents statistically significant difference ($p < 0.05$) based on results of an unpaired student's *t*-test.



Supplementary Figure 7: Validation of TPK1 knockdown and growth effects using alternative siRNA construct. (A) Representative Western blot demonstrating TPK1 expression in WCLs isolated from wild type HCT 116 cells transfected with non-silencing scramble control (SCR CTL) or TPK1 targeted (TPK1 KD2) siRNA for 72 h. (B) Densitometry analysis of fold change in TPK1 expression \pm SD in wildtype HCT 116 cells transfected with TPK1 KD2 compared to SCR CTL siRNA for 72 h. (C) Effect of TPK1 knockdown on tumor cell proliferation demonstrated by mean live cell count \pm SD determined by trypan blue exclusion for wild type HCT 116 cells transfected with SCR CTL or TPK1 KD2 siRNA for 96 h. (*) Represents statistically significant difference ($p < 0.05$) based on results of an unpaired student's *t*-test.



Supplementary Figure 8: Thiamine concentration of cell culture medium. HPLC analysis demonstrating thiamine concentration \pm SD established in TD 1640 and RPMI 1640 following supplementation with 10% fetal bovine serum (FBS) to prepare complete growth medium.

Supplementary Table 1: Research Registry Identification (RRID) for cell lines

Cell line	ATCC catalog number	RRID
MCF7	HTB-22	CVCL_0031
MDA-MB-231	CRM-HTB-26	CVCL_0062
LN-18	CRL-2610	CVCL_0392
U-87 MG	HTB-14	CVCL_0022
Caco-2	HTB-37	CVCL_0025
HCT 116	CCL-247	CVCL_0291
Hutu 80	HTB-40	CVCL_1301

Supplementary Table 2: siRNA constructs used to mediate TPK1 knockdown

Construct	Sense and antisense sequences	Target sequence
Hs_TPK1_5 TPK1 KD1	5'-ccuggugcaucgaaauguatt-3'(sense) 5'-uacauuucgaugcaccagggtt-3' (antisense)	5'-aacctggtgcatcgaaatg-3'
Hs_TPK1_6 TPK1 KD2	5'-gguugucuguagagaugatt-3' (sense) 5'-ucauucucuacagacaacctg-3'(antisense)	5'-caggtgtctgtagagaatga-3'

Supplemental Table 3: Primer sequences and roche universalprobe library probe pairs for real time-PCR analysis

Gene	Forward and reverse primer sequences	Probe
<i>TBP</i>	F: 5'-cggctgtttaactcgcttc-3' R: 5'-cacacccaagaacagtga-3'	3
<i>TPK1</i>	F: 5'-gcctttacccgttgag-3' R: 5'-ccaaaggctgattaagaattacaag-3'	48
<i>LDHA</i>	F: 5'-gtccttgagggaacatggag-3' R: 5'-ttcagagagacaccagcaaca-3'	47
<i>VEGF</i>	F: 5'-cagactcgcttgcaaga-3' R: 5'-gagagatctggtccccgaaa-3'	12
<i>SLC2A1</i>	F: 5'-gccatgtatgtgggtgaa-3' R: 5'-agtccaggccgaacacct-3'	81

Supplementary Table 4: Primary antibodies used for Western blot analysis

Protein of interest (Predicted MW)	Manufacturer (Catalog number)	Dilution	Secondary antibody	Antibody registry ID
TPK1 (27kDa)	Genetex (GTX103943)	1:500	Goat Anti-Rabbit	AB_1952355
LDHA (37kDa)	Genetex (GTX101416)	1:1000	Goat Anti-Rabbit	AB_10726413
b-Actin (42kDa)	Sigma-Aldrich (A2228)	1:1000	Goat Anti-Mouse	AB_476697
HIF-1a (93kDa)	Genetex (GTX127309)	1:1000	Goat Anti-Rabbit	AB_2616089